The incidence of adverse events and other assessments as measure of subject safety.

Mean change in quality of life, relative to the pre-randomization baseline of the Core Study, if assessed during the Core Study.

Changes in the Caregiver Global Impression of Change (CGIC) or Subject Global Impression of Change score, relative to the pre-randomization baseline of the Core Study, if assessed during the Core Study.

Percent reduction from baseline in seizure rates (all types of seizures) in the double-blind phase. Percent reduction in drop attacks (tonic-clonic) and parent/guardian global evaluation at end of study

Evaluation of the safety of oral topiramate as adjuvant therapy for focal epilepsy, Lennox-Gastaut syndrome epileptic seizures and the generalized tonoclonic seizures in adults and children aged 2 years and older.

Safety & tolerability evaluation will be performed by reporting AEs & Clinical labs.

Evaluation of efficacy will be performed with the aid of descriptive statistics.

Overall assessments of the improvement in the seriousness of seizures will be performed.